Ovarian function and sex hormone production with special focus on androgens (testosterone, androstenedione, dehydroepiandrosterone and its sulfate, DHEAS) was followed up during 1.5-20 (mean 9) years after bone marrow transplantation (BMT) in 24 female subjects aged 16-33 (mean 21) years at the last follow-up. All patients had received TBI and high-dose chemotherapy as the preparative regimen. A total of 24 female patients with conventionally treated pediatric hematologic malignancies served as controls. Four of 24 transplanted patients had spontaneous menstruation several years post transplantation, but in only one of them were serum FSH levels normal. Androgen levels of the BMT patients were lower than those of the conventionally treated patients. Subnormal testosterone levels were observed in 43% of BMT patients and subnormal DHEAS levels in 34% of BMT patients, the latter being a constant finding during glucocorticoid therapy for chronic GVHD (cGVHD). These results indicate that ovarian damage is a common late effect in patients transplanted at a young age, still having a seemingly normal pubertal development. Ovarian damage and cGVHD with glucocorticoid therapy are strongly associated with subnormal androgen levels. The clinical consequences of these changes and possible benefits of putative androgen replacement therapy remain to be elucidated. Bone marrow transplantation (BMT) has been an established mode of treatment for severe aplastic anemia and hematologic malignancies for two decades, during which period survival after BMT has significantly improved. Increasing attention has been paid to the quality of life of long-term survivors. Endocrine disturbances after BMT are common problems, in addition to chronic GVHD (cGVHD) and a possible recurrence of the underlying disease. It was initially believed that TBI would cause permanent gonadal damage, evident soon after transplantation. Subsequently, it has been shown, however, that some young female patients experience ovarian recovery, sometimes years after the procedure.
Bone marrow transplantation (BMT) has been an established mode of treatment for severe aplastic anemia and hematologic malignancies for two decades, during which period survival after BMT has significantly improved. Increasing attention has been paid to the quality of life of long-term survivors. Endocrine disturbances after BMT are common problems, in addition to chronic GVHD (cGVHD) and a possible recurrence of the underlying disease. It was initially believed that TBI would cause permanent gonadal damage, evident soon after transplantation. Subsequently, it has been shown, however, that some young female patients experience ovarian recovery, sometimes years after the procedure.
1,2 Even pregnancies with healthy infants have been reported, although infertility is the rule and the risk of spontaneous abortion or of delivery of a low birth weight infant is high. 3 Normal physical strength and activity with good general well being improve the quality of everyday life, the psychosocial and physical aspects of sexuality included. Many factors contribute to female sexual function, including ovarian production of both estrogens and androgens. In adult female bone marrow recipients, there are reports of adverse effects of BMT on sexual health despite adequate hormone replacement therapy (HRT) with estrogens and progestins. 4 In addition, it has been suggested that cGVHD might have an adverse impact on sexual function. 5 In female patients, normally both the ovaries and the adrenal cortex produce androgens. Administration of dehydroepiandrosterone (DHEA), normally secreted in large amounts by the adrenal glands, has been reported to have positive effects on well being and sexuality of women with adrenal insufficiency. 6 It also increases bone density, muscle strength and the sense of well-being in normal elderly men and women. 7, 8 There are no reports on adrenal androgen levels of adult female patients after allogeneic BMT. We have previously reported subnormal levels of androgens, both ovarian and adrenal, in a crosssectional study of young transplanted female adolescents; low ovarian androgen levels were interpreted to reflect ovarian damage. 9 The aim of the present study was to investigate longitudinally ovarian function and sex hormone production, with special focus on androgen levels, in female patients transplanted at a young age and carefully followed up for several years. To avoid the confounding effect of puberty on hormone levels, only patients over 16 years of age were included in this report.
Patients and methods
All consecutive female bone marrow transplant recipients treated at the Hospital for Children and Adolescents, University of Helsinki and followed-up for at least 1 year after a TBI-containing preparative regimen, who were over 16 years of age at the time of the last follow-up, were eligible for this study. The control group consisted of female patients of the same age treated conventionally for hematologic malignancies at the same hospital, with at least 1 year of follow-up after discontinuation of chemotherapy.
Transplanted patients
In total, 24 female patients who had received a BMT at the Hospital for Children and Adolescents, University of Helsinki (n ¼ 23) or at the Huddinge Hospital, Huddinge, Sweden (n ¼ 1) from March 1980 to January 2000 were included in the study (Table 1) . They had been transplanted at ages 4-19 (mean 12) years, and their age at the most recent evaluation ranged from 16 to 33 (mean 21) years. All had been followed up at the Helsinki University Hospital for 1.5-20 (mean 9) years after transplantation. Primary diagnoses included hematologic malignancy (n ¼ 21), retinoblastoma (RBL) (n ¼ 1), severe aplastic anemia (SAA) (n ¼ 1) and myelodysplastic syndrome (MDS) (n ¼ 1) (Table 1) . Before BMT, all patients except those with SAA and MDS had received combination chemotherapy. Cranial irradiation of 18-25 Gy had been given to seven patients and, in addition, one had received spinal irradiation of 12 Gy. As conditioning therapy, the patients had received high-dose chemotherapy with cyclophosphamide (n ¼ 15), cytarabine (n ¼ 8), or etoposide, melphalan and cisplatin (n ¼ 1) plus TBI of 10-14 Gy in single (n ¼ 6) or 5-7 fractions (n ¼ 18). Two patients received autologous stem cells and all the others had allogeneic, either sibling (n ¼ 13), parental (n ¼ 1) or matched unrelated donor (n ¼ 8) grafts. Two patients (nos. 9 and 23, Table 1 ) had relapse of CML at 11 and 28 months after BMT and then received donor lymphocyte infusions (DLI) and interferon therapy but no cytostatic chemotherapy. Remission was achieved in both of them. Of the allogeneic recipients, 10 had no signs of cGVHD, seven had limited and five, including the two DLI patients, had extensive cGVHD. Eight patients received glucocorticoid therapy for cGVHD for 6-54 (mean 21) months, but in three of them cGVHD was no longer active and steroid therapy had been discontinued before this study. Five patients had glucocorticoid therapy for 6, 8, 16, 24 and 30 months during this follow-up. At the time of BMT, 11 patients were prepubertal, four in Tanner stages 2-4 but still premenarcheal and nine had experienced menarche at the age of 10-13.5 years (Table 1) . Ovarian function post transplantation L Hovi et al
Conventionally treated patients
Female patients who were 16-21 (mean 18) years at the last visit, had received conventional chemotherapy based on Nordic or Children's Cancer Group derived protocols for acute leukemia (n ¼ 19) or non-Hodgkin's lymphoma (n ¼ 5), and diagnosed between 0.3 and 14.1 (mean 7.0) years of age were included. 10, 11 Of these patients, 12 had received prophylactic cranial irradiation of 18-24 Gy and two mediastinal irradiation of 24 and 30 Gy, respectively. No one had received radiotherapy to the abdominal area. The post-therapy interval was 3-14 (mean 8) years. They all had experienced normal pubertal development with spontaneous menarche at the ages of 11.0-15.2 (mean 12.8) years and continued to have normal menstrual periods. Five were using contraceptive pills of combined type during some of the time of the follow-up visits.
Methods
The patients were followed up at 6-12-month intervals at the outpatient clinic of the Pediatric Hematology/Oncology Unit. The pubertal development and ovarian function were assessed both clinically and biochemically. Pubic hair and breast development were staged according to Tanner. In addition to history and physical examination, blood samples were collected between 0800 and 1200 hours for hormone measurements. Serum concentrations of testosterone, androstenedione, DHEA, DHEA sulfate (DHEAS), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol were determined using specific radioimmunoassays. 9 The hormone levels were measured 1-10 (median 3) times in each patient during the study period.
The cut-off values for subnormal levels were as follows: testosterone o0.4 nmol/l, androstenedione o1.5 nmol/l, DHEAS o1.6 umol/l and DHEA o6.5 nmol/l; for supranormal level in FSH, 410 IU/l.
Statistical methods
Significances of the differences between groups were calculated using the two-tailed t-test. The mean value of levels measured for each androgen in an individual patient was used for comparison. Categorial variables were compared using the w 2 test.
Results

Pubertal development, menstruation and gonadotropin levels
Of the 15 girls premenarcheal during BMT, followed up for a median of 9.5 years (range 5.5-20) after transplantion, two had normal pubertal development with spontaneous menarche at ages of 11.5 and 12.9 years and 13 had either no (n ¼ 5) or slow (n ¼ 8) pubertal development and received sex hormone replacement therapy (HRT), started at the median age of 13.7 years (range 11.8-16.9). One of them had her menarche at 13.8 years after a 1-year course of low-dose estrogen therapy, three patients continuing with regular menstruation without hormonal support. One of them (patient 9, Table 1 ) had no menstrual bleeding during a 2-year period of post transplant CML relapse, DLI and extensive cGVHD, but she has subsequently resumed spontaneous regular periods ongoing now for 3 years. In addition, three girls had sporadic vaginal bleeding one to four times, two during estrogen therapy, but no regular menstruation occurred without cyclic HRT (Table 1) . Of the nine girls postmenarcheal during BMT, all became amenorrheic, had increased FSH levels and received cyclic HRT starting 0.5-2.5 years (median 0.8) after transplantation. They have been followed up for a median of 3 years (range 1.5-17). In one of them (patient 18, Table 1 ), spontaneous menstruation started 5.5 years after transplantation and continued for 9 years until the age of 29 years, after which it became irregular, the gonadotropin levels increased, and HRT was restarted.
FSH
Among the BMT patients, 4/20 (20%) had FSH within the normal range in some of the samples, normal FSH values during HRT excluded. Supranormal FSH levels during the follow-up were measured in 19/20 (95%) of the BMT patients. Of the four transplanted patients with spontaneous regular menstruation without HRT, three had at least one elevated FSH level (29.7, 25.2 and 40.0 IU/l, respectively) measured during this period and only one patient had all FSH levels within the normal range. Every patient who was receiving HRT had elevated gonadotropin levels documented before the start of hormone therapy. During therapy, both normal and elevated FSH levels were observed.
Among the 23 conventionally treated female patients, all FSH levels measured (43 samples) were within the normal range.
Androgen levels
Testosterone. The individual mean value of all testosterone levels ranged from 0.3 to 0.86 (mean 0.66) nmol/l in the BMT patients. It was lower than in the 24 conventionally treated female patients whose mean testosterone levels, based on 1-5 (median 2) measurements in each patient, ranged from 0.39 to 1.4 (mean 1.089) nmol/l (Po0.001) (Figure 1 ). In total, 10 of 23 (43%) transplanted patients had subnormal testosterone levels (o0.4 nmol/l) during the follow-up period (Figure 2 ). Of the 24 conventionally treated female patients, only one had a subnormal testosterone level (0.34 nmol/l) once.
Androstenedione. The levels of androstenedione correlated well with testosterone (r ¼ 0.446, P ¼ 0.0001). In transplanted patients, the individual mean level of androstenedione ranged from 1.1 to 6.6 (mean 2.5) nmol/l. It was lower than in the 24 conventionally treated female patients whose mean androstenedione level, measured 1-5 (mean 2) times in each patient, ranged from 1.1 to 7.1 (mean 4.7) nmol/l (Po0.001) (Figure 1 ). In total, 14 of 22 (63%) of the transplanted patients had subnormal androstenedione levels (o1.5 nmol/l) during the follow-up period. Of the 24 conventionally treated female patients, one had a single subnormal level (1.1 nmol/l) documented.
DHEAS and DHEA. The levels of DHEAS and DHEA correlated well with each other (r ¼ 0.805, P ¼ 0.0001). The mean levels of transplanted patients did not differ significantly from those of the conventionally treated female patients. In transplanted patients, the individual mean DHEAS levels ranged from 0.3 to 12.3 (mean 3.6) mmol/l, while in the 24 conventionally treated female patients the mean DHEAS level, based on 1-5 (mean 2) measurements in each patient, ranged from 1.6 to 9.6 (mean 5.1) mmol/l (P ¼ 0.053) (Figure 1 ). In total, eight of 23 (34%) transplanted patients had subnormal DHEAS levels (o1.6 umol/l) during the follow-up (Figure 3 ). Of the 24 conventionally treated patients, one had a subnormal DHEAS level in two out of three samples (1.2 and 1.5 mmol/l), all the others being within the normal range.
Ovarian function and testosterone
During ovarian dysfunction (FSH410 IU/l), subnormal testosterone levels were observed in nine of 21 (43%) transplanted patients. Ovarian recovery after BMT, as judged by FSH o10 IU/l without HRT, was seen in four patients and none of them had subnormal testosterone levels during that period (Figure 2) .
cGVHD, glucocorticoid therapy and androgens
Subnormal testosterone levels were found in 9/12 BMT patients with cGVHD in contrast to 1/9 patients without cGVHD (w 2 test, P ¼ 0.0037) Four patients had the testosterone level measured during glucocorticoid therapy for cGVHD. One of them had ovarian recovery during this time and her testosterone levels were within the normal range (0.4-0.6 nmol/l) on three occasions during this period (patient 9 in Table 1 ). All other testosterone levels of these four patients were very low (0.1-0.2 nmol/l).
All the five patients receiving glucocorticoid therapy for cGVHD (prednisolone, ranging from 80 mg daily to 5 mg q.o.d.) had subnormal DHEAS levels measured in all their samples during that period (n ¼ 10, range 0.2-1.5 mmol/l). Although not on glucocorticoid therapy, five transplanted patients still had subnormal DHEAS levels: 3/9 among those with cGVHD and 2/9 with no signs of cGVHD. Apart from during glucocorticoid therapy, no patient had continuously low DHEAS levels during the follow-up (Figure 3) .
The DHEA levels were comparable to DHEAS: the four patients receiving glucocorticoid therapy had subnormal values (o6.5 nmol/l) in all of their samples (n ¼ 9, range 0.4-4.6 nmol/l). When not receiving glucocorticoids, 8/17 had subnormal DHEA levels in some of the measurements.
The five patients who developed cGVHD prompting glucocorticoid therapy and who had concurrent ovarian (1) mean7s.d., 9 (2) mean, 16-84% range, 12 and (3) mean7s.d. 13 dysfunction all had subnormal androgen levels in all of their samples.
Discussion
According to our study, the majority of young female patients receiving BMT and TBI had problems with pubertal development. Only three of 15 girls transplanted prior to the menarche had normal pubertal development with a spontaneous menarche, one of them with low-level estrogen support. Higher percentages, some even exceeding 50%, of girls experiencing spontaneous puberty after BMT have been reported in some previous studies. 2 Younger age at BMT and fractionated TBI as opposed to single fraction are the main favorable prognostic factors for normal ovarian function and may explain most of the differences between reports. 14, 15 However, the majority of female patients with regular menstruation still had elevated FSH levels both in the present study and in previous reports, indicating ovarian damage in spite of seemingly normal pubertal development.
1,2 Furthermore, in this study there were three female patients with 1-4 irregular sporadic menstrual bleeds before cyclic HRT was started. In total, only one out of the 24 young female patients had regular menstruation and a normal FSH level at the last follow-up. Longitudinal information regarding regularity of menstruation is seldom reported in the studies. Continuous followup and close monitoring of ovarian function is needed for assessing possible fertility and the need for HRT.
A high risk of spontaneous abortion and premature delivery has been reported in pregnancies of transplanted female patients. 3 The risk of early menopause has also been suggested. 16 So far, no effective means of protecting the ovaries during high-dose chemoradiotherapy have been developed. Identification of female patients with good ovarian function after transplantation is important for correct information regarding contraception and family planning, and also in case new techniques for assisted reproduction, for example, cryopreservation of embryos or use of a surrogate uterus, are being considered.
Testosterone levels of transplanted patients were clearly lower than those of conventionally treated patients or healthy female patients, also reported in our previous work. 9 This was suggested as due to ovarian damage, and we attempted to analyze the underlying factors further. The factors associated with a subnormal serum testosterone concentration were ovarian dysfunction but also cGVHD and glucocorticoid therapy. Owing to the small number of patients, the independent role of each factor was difficult to define.
Ovarian dysfunction after BMT has been mainly attributed to radiotherapy and high-dose chemotherapy, particularly busulfan, 3 and the main target organs of cGVHD have been documented to be skin, liver and gastrointestinal tract. One might also speculate about the role of ovarian cells as the target for cGVHD. Testosterone levels of girls transplanted in other centers have not been reported, but in adult female patients testosterone levels were found to be within the normal range after allogeneic BMT. 17, 18 In female patients, approximately half of the testosterone is produced by the ovaries, requiring contribution of both granulosa and theca cells, and the other half by the adrenal gland and other tissues with possibly different vulnerability to irradiation. This function of different cells may be age-related. The mean value of DHEAS levels in the BMT patients did not differ from that of the conventionally treated patients. However, 34% of the transplanted patients had a subnormal DHEAS level in some of their samples. These findings are in accordance with our previous study. 9 DHEAS is secreted mainly by the adrenal cortex. The secretion of both DHEA and DHEAS is stimulated by ACTH. Our novel finding is that adrenal androgen levels were low in patients receiving glucocorticoid therapy for cGVHD, suggesting steroid-induced adrenal suppression.
Lack of DHEA and DHEAS results in loss of pubic and axillary hair and osteoporosis. Among the transplanted female patients, 6/19 had scanty or nonexisting axillary and pubic hair although this did not correlate with the actual DHEAS levels (data not shown). Bone mineral density was not measured. In a placebo cotrolled study, 4 months of replacement therapy with DHEA in women with adrenal insufficiency resulted in significant improvement of depression and anxiety, general well-being and the psychological and physical aspects of sexuality. 6 Treatment with DHEA was considered justified in patients with adrenal insufficiency whose strength and well-being were subnormal. Prolonged high-dose glucocorticoid therapy was also thought to be a possible indication for DHEA therapy, especially in diseases with a high risk of osteoporosis. 19 Some patients with cGVHD may receive glucocorticoid therapy for several years and the DHEAS level, as shown in this study, may be low while they are receiving a rather small dose of prednisolone (5 mg q.o.d.). Thus, some clinical symptoms and the lack of overall well-being during cGVHD might be due to subnormal levels of DHEA and its sulfate. These patients also have an increased risk of osteoporosis 20 and metabolic syndrome. 21 Despite different etiologies of hypoandrogenism in women after BMT, this condition has significant adverse effects on health and general well-being. Therefore, a controlled study of the effect of DHEA therapy for patients receiving prolonged glucocorticoid therapy for cGVHD might be warranted.
There are multiple reports on ovarian function after BMT, but only very few on the sexuality of these patients. Watson et al evaluated the sexual health of 479 patients with AML including 166 female patients receiving conventional chemotherapy and 95 female patients who had received autologous grafts or allogeneic transplants from sibling donors. The follow-up time after BMT was 12-22 months. None was receiving steroids. In all, 78% of allogeneic and 58% of autologous BMT patients were taking HRT. Highly significantly decreased sexual functioning was reported by the BMT patients as compared to the conventionally treated patients. Poorer sexual function correlated with increased fatigue, which was more common in the allogeneic BMT patients.Women apperared to be affected more often than men. 5 Even if addition of androgens to HRT was studied half a century ago, there are still hardly any controlled studies on the effect of testosterone on the sexual life of female patients. Quite recently it was shown that addition of testosterone improved the quality of sexual life in oophorectomized women. 22 The quality of life issues were not investigated in our patients. Further studies should be pursued to reveal a possible correlation between quality of life and hormone levels, as well as to investigate the possibility of improving quality of life in some BMT patients with the addition of androgens to the estrogenprogestin HRT.
In conclusion, we demonstrated that young female transplant patients with ovarian dysfunction and cGVHD treated with glucocorticoids are at high risk of low serum androgen levels. The clinical consequences of the low androgen levels, as well as the possible benefits of HRT with androgens, remain to be elucidated.
